Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug.

A Lancaster University professor says a landmark ruling by the African Court of Human and People's Rights against the government of Tanzania for not upholding the rights of people with albinism is ...